Hyderabad-based Gland Pharma on Friday said the cash in books will be used for merger and acquisitions (M&As) and growth after it made a strong debut on the exchanges today.
Speaking in an interview with CNBC-TV18, Srinivas Sadu, managing director, said, "We have a resilient business and launches are in the pipeline."
According to him, there are not many players in the business-to-business (B2B) injectable industry.
On growth, Sadu said, "Going forward, growth will be in line with last year's performance. The company is doing well in Africa, Brazil, and Canada and filing new products in all geographies."
For the entire interview, watch the video